Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

 Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

Shots:

  • Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for conducting P-II trial for IONIS-FB-LRx in patients with Geographic Atrophy (GA)
  • Under the agreement, Roche has option to license IONIS-FB-LRx post trial completion and will hold global development and commercialization rights
  • IONIS-FB-LRx is an antisense drug used for reduction of Factor B(FB) in patients with GA and is developed by Ionis’ LIgand Conjugated Antisense (LICA) technology

Click here to read full press release/ article | Ref: Ionis Pharma | Image: The Pharma Letter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post